Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 20, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric disclosed relates to the share buyback transaction:
- Shares Purchased: 1,250,000 ordinary shares.
- Purchase Price: 1,155.38 pence per share.
- Treasury Holdings: 494,794,158 shares (representing 8.95% of total voting rights).
- Shares in Issue: 5,530,498,083 (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the November 20, 2007 purchase. The filing does not provide comparative financial data against prior periods to assess changes in operational performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory conformity statement.
Investor Verification Points
- Verify the total cost of the 1,250,000 shares purchased at 1,155.38 pence per share.
- Confirm the updated total voting rights calculation based on the 5,530,498,083 shares in issue.
- Check subsequent filings for the impact of the 8.95% Treasury holding on earnings per share calculations.